Drug Trial Radar · NCT02100748
A Study of TRV130 for the Treatment of Pain After Bunionectomy
Last checked: Nov 20, 2026Latest source record: Sep 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
333
Actual
Start
Apr 2014
Primary completion
Oct 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- Trevena Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 1, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the analgesic efficacy of IV TRV130 compared with placebo in patients with acute postoperative pain after bunionectomy.
Conditions
- Acute Pain
Interventions
TRV130Drug
TRV130 1 - 4 mg will be administered every 4 hours
MorphineDrug
Morphine 4 mg will be administered every 4 hours
PlaceboDrug
Placebo will be administered every 4 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time Weighted Average (TWA) Change From Baseline in Pain Score Over 48 Hours Between TRV130 and PlaceboTime frame: 48 hours
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Premier Research
Phoenix, Arizona
Chesapeake Research Group
Pasadena, Maryland
Premier Research
Austin, Texas
Jean Brown Research
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.